Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRNA and protein synthesis mechanisms · RNA modifications and cancer · Biochemical and Molecular Research
Park MY, Bae S, Heo JA, et al. Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects. Clin. Transl. Sci. 2023;16(7):1163–1176. doi: 10.1111/cts.13518. Epub 2023 Apr 24. PMID: 37095713; PMCID: PMC10339703.
The authors are adding the following information to the title page:
“Min Young Park and Sungyeun Bae contributed equally to this work.”
These authors made significant joint contributions to the work and should be acknowledged equally.